slams Beijing’s crackdown on freedom fighter Jimmy Lai and says U.S. weakness on sanctions emboldens China and Putin putting Asia at risk on ‘Mornings with Maria.’ D.C. residents drive law enforcement out of neighborhood 2 more beachfront homes near ...

Asia shares trade mixed on Thursday, as tech shares stabilized from their recent losses. Australian markets hit record highs, driven by strong business activity data for August. On the geopolitical front,

The success or failure of China's security initiatives in Southeast Asia depends on the domestic politics of Southeast Asian states and the Chinese leadership's priorities on the South China Sea.

From China souring on Canadian canola to Chinese mini dramas exploring potential in US and beyond, here’s a round-up from today’s coverage.

Indian Prime Minister Narendra Modi has met China's top diplomat and hailed the “steady progress” made in improving the countries' relationship after a yearslong standoff between the nuclear-armed powers.

China is willing to cooperate with Pakistan in industry, agriculture and mining, Foreign Minister Wang Yi told Pakistani counterpart Ishaq Dar in Islamabad on Thursday, according to a readout of the meeting released by Wang's ministry.

India has successfully test-fired an indigenously developed intermediate-range ballistic missile capable of carrying a nuclear warhead deep into the territory of its geopolitical rival, China, just as Prime Minister Narendra Modi prepares for his first visit there in years.

About 500 robot athletes from 16 countries competed in Beijing as the United States and China race each other to shape the future of AI.

China has been installing solar panels at a blistering pace, far faster than anywhere else in the world, and the investment is starting to pay off. A study released Thursday found that the country’s carbon emissions edged down 1% in the first six months of the year compared to a year earlier, extending a trend that began in March 2024.

Bunge Global SA diverted a cargo of Argentine soybean meal bound for China to Southeast Asia due to concerns it might fail to meet Chinese quality specifications, people with knowledge of the matter said.

China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 million Chinese yuan ($34.8 million) upfront. | China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 million Chinese yuan ($34.